Subscribing to the notion that the best defense is a good offense, Johnson & Johnson (JNJ) is appealing directly to large swaths of the public not to believe claims made by Pfizer (PFE) in a lawsuit that the health care giant used illegal tactics to protect a best-selling drug.

In a missive posted on its web site late last week and addressed to patients, doctors, insurers, and employers, J&J argued that Pfizer is, essentially, whining about an inability to successfully capture market share for its biosimilar version of Remicade, a blockbuster treatment for rheumatoid arthritis and other diseases.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • As I may have previously observed, the Pfizer approach seems mild compared to the J&J measures again Abbott for Humira, pre-AbbVie, some years ago. That is, at least, one person’s observation. I would be curious to see what “oii” (of happy memory) might think.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy